Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
International Journal of Medical & Pharmaceutical Sciences
A narrative review synthesizing evidence from pivotal trials to evaluate GLP-1 receptor agonists for weight management, offering clinical recommendations rather than reporting original research.
A narrative review synthesising current understanding of obesity management across non-pharmacological, herbal, approved pharmacological and emerging therapeutic strategies, without presenting new primary data or systematic evidence synthesis.
This is an official multisociety hypertension guideline from the AHA/ACC that synthesizes evidence across populations and provides clinical recommendations for practice.
International Journal of Medical & Pharmaceutical Sciences
A narrative review synthesizing evidence from pivotal trials to provide clinical recommendations on GLP-1 agonist use for weight management, addressing efficacy, safety and individualized patient selection.
A narrative review synthesizing existing evidence on GLP-1 biology and dietary interactions; presents current understanding and identifies research gaps rather than reporting new empirical data or a definitive clinical trial.
A narrative review synthesizing evidence from multiple trials (FLOW, cardiovascular outcome trials) to position incretin-based therapies within the therapeutic landscape for CKD, without reporting a primary study result or meta-analysis.
International Journal of Medical and Biomedical Studies
A systematic review identifying associations between lipids and glycemic control in T2DM, but explicitly concluding that most evidence is cross-sectional, causality cannot be distinguished, and clinical utility remains uncertain; raises questions rather than answering them.
This is a literature review synthesizing evidence on GLP-1 and MC4R agonists for obesity and type 2 diabetes, presenting expert assessment of mechanisms and clinical efficacy rather than reporting original trial data.